Application 202172
- Type
- NDA
- Sponsor
- WATSON LABS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ROSUVASTATIN ZINC | ROSUVASTATIN ZINC | TABLET; ORAL | 5MG | No | No |
| 002 | ROSUVASTATIN ZINC | ROSUVASTATIN ZINC | TABLET; ORAL | 10MG | No | No |
| 003 | ROSUVASTATIN ZINC | ROSUVASTATIN ZINC | TABLET; ORAL | 20MG | No | No |
| 004 | ROSUVASTATIN ZINC | ROSUVASTATIN ZINC | TABLET; ORAL | 40MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.